Replies to post #84458 on Biotech Values

[ghmm]

What are your thoughts on substrate reduction therapies? Or do you think ERT is the best approach for the foreseeable future?

thanks in advance!

[mcbio]

Re: FOLD-Plicera Phase 2 failure

I never had much faith in their chaperone technology

It's important to note that Plicera is not FOLD's lead drug. Notwithstanding the fact that the stock is down over 26% right now after hours, this news should have no effect or implications for their lead drug, Amigal, which has shown good clinical success to date against Fabry's disease.